Nonalcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity four
decades ago. However, the condition has become the centre of attention within hepatology …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of
chronic liver disease in children and adolescents. Over the past 5 years, developments have …

These recommendations are based on the following:(1) a formal review and analysis of the
recently published world literature on the topic [Medline search up to June 2011];(2) the …

Guidelines; 1 (3) guideline policies of the three societies approving this document; and (4)
the experience of the authors and independent reviewers with regards to NAFLD. Intended …

Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, is
the most common chronic liver disease, and the prevalence is rapidly increasing worldwide …

Non-alcoholic fatty liver disease (NAFLD) is now the most frequent chronic liver disease that
occurs across all age groups and is recognized to occur in 14%-30% of the general …

Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis
B patients under long‐term therapy with potent nucleos (t) ide analogues is currently …

Nonalcoholic fatty liver disease (NAFLD) is the liver injury most often associated with
disorders of insulin resistance, including obesity, diabetes and the metabolic syndrome. The …

Nonalcoholic fatty liver disease (NAFLD) and its more severe subtype, nonalcoholic
steatohepatitis (NASH), are steatotic liver diseases that develop in the absence of significant …